3D printing of personalized medicine.

We develop medicines printed at the exact dose, for the specific patient, on demand, and are building a national network of pharmacies, hospitals, CDMOs and government sites that make them close to patients.

Partner with us Investor presentation

CSE: PHRM · OTCQB: PHRRF

CraftTab 4-in-1 polypill, a multi-layer 3D-printed tablet, held between two fingers

Assorted 3D-printed dosage forms: tablets, chewables and gummies

Liquid-filled 3D-printed chewable held in a gloved hand

I'm here to…

InvestCatalysts, filings and alertsInvestors →Partner or licenseSix ways to work with usPartnering →Use the platformPrinters, formulation and contract manufacturingM3DICINES ↗Join the networkPharmacies, hospitals, CDMOs, research and government sitesM3DICINES™ Network →Read newsNewsroom, media kit and contactNewsroom →

Exclusive North American CraftMake™ distributor

U.S. 503A Center of Excellence

Partnered GMP contract manufacturer

Why 3D-printed medicines matter

Mass manufacturing leaves many patients poorly served.

Conventional manufacturing pays off only at hundreds of thousands to millions of identical units. Six needs fall outside that.

Personalized dosesOften only injections or a few fixed strengths

Children and rare diseasesAdult tablets cut at home; about 95% of rare diseases have no FDA-approved treatment

Discontinued medicinesDemand became too small for a production line

Drug shortagesMade in central plants, often overseas, far from patients

Clinical and research supplyMany strengths, in batches of a few hundred units

National emergenciesLimited stockpiles in a few standard strengths and forms

Why pharmaceutical 3D printing →

Business model

Two pillars. One platform.

The pipeline creates proprietary value. The network and partners create reach, adoption and recurring revenue, and surface new products. Each feeds the other.

We ownthe products, formulations and network

Personalized 503A products, including peptides and ketamine

FDA rare and ultra-rare disease programs

Psychedelic, discontinued and short-supply medicines

The M3DICINES™ National Network and preparedness nodes

Explore the pipeline →

We openthe platform to partners

Network placements: exclusive CraftMake™ distribution

M3DICINES™ formulation licensing and white-label products

CDMO services and research collaborations

Government readiness contracts, if awarded

Ways to partner →

Our platform

One validated recipe prints any dose.

1 · Formulate

Validated formulation

Proprietary blends, GRAS excipients and printed geometries.

2 · Personalize

Digital recipe

Print files, parameters and methods: the manufacturing instructions for each dose.

CraftMake Production Plus pharmaceutical 3D printer

3 · Print

CraftMake™ prints it

GMP-ready, heat-free and UV-free, with a digital batch record for every dose.

1%Precision

No heat, no UVRoom-temperature printing

8*Dosage forms

4Release profiles

Our platform See CraftMake™ on M3DICINES ↗

*Oral films to be confirmed with Craft Health. 1% reflects Craft Health system specifications.

Product pipeline

Small batches, big gaps.

Our pipeline spans five areas where a precise dose, a combination or a small batch makes a medicine possible.

Explore the pipeline →

ProgramStatusNext milestone

503A personalized products

StatusLaunch planned

Next milestoneFirst launches Q4 2026; ketamine dissolvable tablet Q1 2027

Rare pediatric disease program

StatusDesignations

Next milestoneApplications October 2026 · NDA Q4 2028 (target)

Ultra-rare disease program

StatusEvaluating

Next milestoneProgram selection, 2027–2028

Psychedelic medicines

StatusPlanned

Next milestoneTrial and access supply, 2027–2028

Discontinued & short-supply medicines

StatusEvaluating

Next milestoneCandidate selection, 2027–2028

Timelines are internal estimates and forward-looking. 503A products are compounded for individual patients and are not FDA-approved.

503A personalized productsPeptides, Rx wellness and ketamine for telehealthLearn more →Rare & ultra-rare diseasesWeight-banded doses with priority review voucher potentialLearn more →Psychedelic medicinesPrecisely dosed supply for trials and special accessLearn more →Discontinued & short-supplyBringing back medicines patients still need, made closer to themLearn more →Medical countermeasuresA planned preparedness network of qualified nodesLearn more →

Partnering

Six ways to work with PharmaTher.

1 · Place

Join the network

Place CraftMake™ as M3DICINES™ Network infrastructure, with validated formulations from day one.

2 · License

Formulation licensing

M3DICINES™ formulations for personalized doses, combinations and controlled release.

3 · Sell

White-label products

Pharma, peptide and nutraceutical products for telehealth and consumer-health brands.

4 · Develop

CDMO services

Formulation, clinical trial supply and small-batch manufacturing.

5 · Discover

Research collaborations

Feasibility and formulation science with pharma, universities and government.

6 · Prepare

Emergency readiness

Readiness contracts, if awarded, keep qualified nodes ready for emergencies.

Start a partnering conversation Become a Network Partner on M3DICINES ↗

For investors

The opportunity in front of us.

US$295BPeptide therapeutics by 2033up from US$141B in 2025

US$1.2TPersonalized medicine by 2033up from US$567B in 2024

US$59BMedical countermeasures by 2030up from US$41B in 2025

Catalysts and what each unlocks

Q4 2026Network launch; first 503A productsProduct revenue begins

Q1 2027Ketamine dissolvable tablet; pre-IND meetingTelehealth sales; first ANDA payments expected

Next 12 monthsUp to 50 placements; preparedness demoProductive nodes and recurring revenue

2027–28Licences, readiness contracts, new programsUltra-rare, psychedelic, discontinued and short-supply

Q4 2028Rare pediatric NDA (target)Path to orphan exclusivity

BeyondFirst FDA approval of a PharmaTher printed medicinePotential priority review voucher

Market sizes are third-party estimates of total markets, not PharmaTher revenue. Targets and timelines are internal estimates and forward-looking. Forward-looking statements